Glenn E. Dale
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers.
Journal: Antimicrobial agents and chemotherapy
Published: March 02, 2026
Revival of Ethionamide by Alpibectir.
Journal: The New England journal of medicine
Published: February 18, 2026
BVL3572S inhibits HisC and AlaA, exploiting vitamin B6 dependency to kill Mycobacterium tuberculosis.
Journal: Cell chemical biology
Published: October 28, 2025
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models.
Journal: The Journal of antimicrobial chemotherapy
Published: July 20, 2025
Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis.
Journal: Nature communications
Published: March 07, 2025
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.
Journal: The Journal of antimicrobial chemotherapy
Published: December 12, 2023
Structure-activity relationships of actively FhuE transported rifabutin derivatives with potent activity against Acinetobacter baumannii.
Journal: European journal of medicinal chemistry
Published: January 13, 2023
Design and synthesis of water-soluble prodrugs of rifabutin for intraveneous administration.
Journal: European journal of medicinal chemistry
Published: May 10, 2022
In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.
Journal: The Journal of antimicrobial chemotherapy
Published: May 08, 2020
Author Correction: Chimeric peptidomimetic antibiotics against Gram-negative bacteria.
Journal: Nature
Published: November 24, 2019
Last Updated: 09/26/2026